Laura Benedetto, DO
Osteopathic Manipulative Medicine · Glastonbury, CTNPI 1710951009
Payments from drug & device makers
Across 151 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$243
- E.r. Squibb & Sons, L.L.C.$230
- Merz North America, Inc.$221
- LEO Pharma Inc.$198
- Johnson & Johnson$181
- plus $981 from 14 others
What the payments were for
- Food & beverage$3,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,103 |
| UCB, Inc. | 10 | $243 |
| E.r. Squibb & Sons, L.L.C. | 14 | $230 |
| Merz North America, Inc. | 2 | $221 |
| LEO Pharma Inc. | 10 | $198 |
| Johnson & Johnson | 8 | $181 |
| Regeneron Healthcare Solutions, Inc. | 5 | $150 |
| Sun Pharmaceutical Industries Inc. | 5 | $139 |
| Galderma Laboratories, L.p. | 6 | $123 |
| Sanofi | 5 | $121 |
| Incyte Corporation | 5 | $108 |
| Dermavant Sciences, Inc. | 3 | $81 |
| Novartis | 3 | $71 |
| Pfizer | 4 | $62 |
| Lilly USA, LLC | 3 | $55 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Botanix SB Inc | 1 | $16 |
| Almirall LLC | 1 | $15 |
| Organon | 2 | $5 |
How this compares
Too few osteopathic manipulative medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 26 | $98,663 |
| Dupixent SyringeDupilumab | 14 | $96,050 |
| Metronidazole | 22 | $1,210 |
| Clobetasol Propionate | 22 | $613 |
| Clindamycin Phosphate | 12 | $464 |
| Fluorouracil | 12 | $454 |
| Doxycycline Monohydrate | 15 | $433 |
| Ciclopirox | 14 | $422 |
| Alclometasone Dipropionate | 13 | $373 |
| Ketoconazole | 27 | $301 |
| Ammonium Lactate | 12 | $180 |
| Azelaic Acid | 11 | $168 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 18 | $98 |
Paid to pharmacies, not to this prescriber.
Other osteopathic manipulative medicine in Glastonbury
- Domenick MasielloRidgefield$0
- Nicholas PalermoManchester$0
- Dominick RotoPutnam$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.